Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

BACKGROUND AND OBJECTIVE: Mirikizumab is a humanized anti-interleukin-23-p19 monoclonal antibody being developed for ulcerative colitis and Crohn’s disease. This analysis characterized mirikizumab pharmacokinetics using phase II and III trial data from patients with moderately to severely active ulc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Laiyi, Friedrich, Stuart, Zhang, Xin Cindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520102/
https://www.ncbi.nlm.nih.gov/pubmed/37610533
http://dx.doi.org/10.1007/s40262-023-01281-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520102/
https://www.ncbi.nlm.nih.gov/pubmed/37610533
http://dx.doi.org/10.1007/s40262-023-01281-z

Ejemplares similares